UroGen Pharma (NASDAQ:URGN) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a research report report published on Friday,Benzinga reports. The firm currently has a $25.00 target price on the stock.

A number of other equities research analysts have also recently commented on the company. Guggenheim initiated coverage on UroGen Pharma in a report on Thursday, August 22nd. They set a “buy” rating and a $40.00 target price on the stock. Oppenheimer restated an “outperform” rating and set a $40.00 price objective on shares of UroGen Pharma in a report on Wednesday, October 16th. EF Hutton Acquisition Co. I upgraded UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of UroGen Pharma in a report on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, UroGen Pharma currently has an average rating of “Buy” and a consensus target price of $43.70.

UroGen Pharma Stock Performance

Shares of NASDAQ:URGN opened at $12.29 on Friday. The business’s fifty day moving average price is $12.28 and its two-hundred day moving average price is $13.96. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. UroGen Pharma has a one year low of $10.60 and a one year high of $20.70.

UroGen Pharma (NASDAQ:URGN) last announced its earnings results on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.29. The company had revenue of $25.20 million for the quarter, compared to analyst estimates of $24.22 million. During the same quarter last year, the company posted ($0.68) EPS. Sell-side analysts forecast that UroGen Pharma will post -3.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in URGN. Point72 Asset Management L.P. raised its position in UroGen Pharma by 120.3% in the second quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock valued at $41,099,000 after purchasing an additional 1,337,257 shares during the period. Millennium Management LLC raised its position in UroGen Pharma by 2,672.0% in the second quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock valued at $19,480,000 after purchasing an additional 1,119,019 shares during the period. Cowen AND Company LLC raised its position in UroGen Pharma by 29.1% in the second quarter. Cowen AND Company LLC now owns 2,099,482 shares of the company’s stock valued at $35,229,000 after purchasing an additional 472,893 shares during the period. Vestal Point Capital LP purchased a new position in UroGen Pharma in the third quarter valued at about $5,080,000. Finally, Great Point Partners LLC raised its position in UroGen Pharma by 10.9% in the second quarter. Great Point Partners LLC now owns 2,906,259 shares of the company’s stock valued at $48,767,000 after purchasing an additional 285,714 shares during the period. Institutional investors and hedge funds own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.